Description: Virtual - Session 2D: Navigating Risk Management in Gender - Affirming Care

Description: While intended to assist health plan actuaries responsible for stress testing and ORSA filings, this session will also be informative for actuaries interested in communicating the impact of potential catastrophic events for health plans to their management and board. It will begin with a discussion of event thresholds for stress tests and their impact on capital and financial statements. Presenters will take a detailed look at several catastrophic event case studies (historical and hypothetical) in the following areas: healthcare specific (e.g. pandemic, specialty Rx), financial institution/credit market, operational/business, strategic and multi-event scenarios.</

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: The National Association of Insurance Commissioners (NAIC) is working on changes to the health risk-based capital (RBC) formula. Will your RBC ratio improve or deteriorate under the new formula? And what can you do about it?

Description: While the higher general inflation in the broader U.S. economy hasn't emerged in the healthcare market (yet); there is expectations for it to have a lagged impact especially as the full impact of COVID on suppressed utilization emerges. As the healthcare system transitions past COVID, overall costs are expected to trend higher due to overall inflationary pressures as well as new treatments such as the highly anticipated new gene and cell therapies often with costs over millions of dollars.As costs rise, more companies are looking to self-insure their health insurance to control cost increases and are leveraging innovative stop loss programs including captives. Captive insurance markets have seen significant growth and diverse implementations allowing companies to self-fund while managing the risk of large claims and increasing costs. Payers are also looking to control costs and implement value based payment schemes to bend the trend curve and manage costs. Medicare has also adopted new value based payment programs (ACO Reach) which will impact commercial payers and are important to understand. Come gain an understanding of the historical and projected future medical cost drivers including the projected impact of new therapies and then impact on the stop loss markets. Additionally, you'll gain a deeper understanding on how recent innovations in the stop loss market such as the growth in the captive market, level funded and aggregate only products have helped employers manage their costs and overall risk profile.

Description: Session 3G: Enhancing ERM - Practical Applications of ASOP 46 and ASOP 47

Description: Session 8A: ORSA for Health Plans - Using ORSA to Drive Health Plan Risk Strategy

Description: Gather with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, pension, investment, product strategy, and more.

Description: "Can you answer the question 'what are the chances we will lose more than $1 million next year?' without saying 'it depends'? If you miss a projection, can you quantify the chances that the miss was due to random variation vs. an incorrect projection? ten in as presenters demonstrate how to answer these questions and others using total risk analysis. Total risk analysis includes quantifying both the random variation risk and the projection risk associated with actuarial functions like pricing and reserving. After attending this session, you will be able to describe total risk analysis, apply total risk analysis to many actuarial functions."

Description: Virtual - Session 8B: The Future of Transplantation and Risk Management